Table 4 Complications, treatment and outcomes of patients with COVID-19

 Shock

16/116 (13.8)

0/61 (0.0)

16/55 (29.1)

< 0.0001

 Acute cardiac injury

23/116 (19.8)

4/61 (6.6)

19/55 (34.5)

0.001

 Acute respiratory distress syndrome

20/116 (17.2)

0/61 (0.0)

20/55 (36.4)

< 0.0001

 Liver dysfunction

15/116 (12.9)

2/61 (3.3)

13/55 (23.6)

0.0011

 Acute kidney injury

3/116 (2.6)

0/61 (0.0)

3/55 (5.5)

0.0565

 Acute heart failure

21/116 (18.1)

3/61 (4.9)

18/55 (32.7)

0.0002

 Administration of oseltamivir

91/116 (78.4)

46/61 (75.4)

45/55 (81.8)

0.4019

 Administration of lopinave/litonawe (LPV/r)

74/116 (63.8)

42/61 (68.9)

32/55 (58.2)

0.2325

 Administration of arbidolhydrochloride

27/116 (23.3)

15/61 (24.6)

12/55 (21.8)

0.7243

 Administration of ribavirin injection

71/116 (61.2)

37/61 (60.7)

34/55 (61.8)

0.8979

 Administration of antibiotics

113/116 (97.4)

58/61 (95.1)

55/55 (100.0)

0.0956

 Use of antifungal medications

12/116 (10.3)

0/61 (0.0)

12/55 (21.8)

0.0001

 Administration of systemic corticosteroids

55/116 (47.4)

14/61 (23.0)

41/55 (74.5)

< 0.0001

 Oxygen inhalation

103/116 (88.8)

50/61 (82.0)

53/55 (96.4)

0.0141

 Noninvasive ventilation

18/116 (15.5)

0/61 (0.0)

18/55 (32.7)

< 0.0001

 Invasive mechanical ventilation

10/116 (8.6)

0/61 (0.0)

10/55 (18.2)

0.0005

 Extracorporeal membrane oxygenation

3/116 (2.6)

0/61 (0.0)

3/55 (5.5)

0.0646

 Use of intravenous immunoglobin

74/116 (63.8)

25/61 (41.0)

49/55 (89.1)

< 0.0001

 Use of thymopeptidesinjection

92/116 (79.3)

45/61 (73.8)

47/55 (85.5)

0.1209

 Traditional Chinese medical herbal treatment

103/116 (88.8)

55/61 (90.2)

48/55 (87.3)

0.2955

 Discharge from hospital

109/116 (94.0)

61/61 (100.0)

48/55 (87.3)

0.0040

 Death

7/116 (6.0)

0/61 (0.0)

7/55 (12.7)

0.0040